The LIBERATE tibolone trial in breast cancer survivors

Maturitas

Volumn 63, Issue 1, 2009, Pages 1-3

  Speroff, Leon ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; PLACEBO; TAMOXIFEN; TIBOLONE;

ADJUVANT THERAPY; ADULT; AGED; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EDITORIAL; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; VAGINAL DRYNESS; VASOMOTOR DISORDER;

BREAST NEOPLASMS; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; NORPREGNENES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVORS;

EID: 67349086303     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.03.001     Document Type: Editorial

References (15)

1. Kenemans P., Bundred N.J., Foidart J.-M., et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol January (2009) 10.1016/S1470-2045(08)70341-3
2. de Gooyer M.E., Deckers G.H., Schoonen W.G.E.J., Verheul H.A.M., and Kloosterboer H.J. Receptor profiling and endocrine interactions of tibolone. Steroids 68 (2003) 21-30
3. Cummings S.R., Ettinger B., Delmas P.D., et al. The effects of tibolone in older postmenopausal women. New Engl J Med 359 (2008) 697-708
4. Santner S.J., Feil P.D., and Santen R.J. In situ estrogen production via estrone sulfatase pathway in breast tumors: relative importance versus aromatase pathway. J Clin Endocrinol Metab 59 (1984) 29-33
5. Chetrite G.S., Cortes-Prieto J., Philippe J.C., Wright F., and Pasqualini J.R. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72 (2000) 23-27
6. van de Ven J., Donker G.H., Spsrong M., Blankenstein M.A., and Thijssen J.H.H. Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells. J Steroid Biochem Mol Biol 81 (2002) 237-247
7. Purohit A., Malini B., Hooymans C., and Newman S.P. Inhibition of oestrone sulphatase activity by tibolone and its metabolites. Horm Metab Res 1 (2002) 1-6
8. Chetrite G.S., Kloosterboer H.J., Philippe J.C., and Pasqualini J.R. Effect of Org OD14 (Livial) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MDF-7 and T-47D, and hormone-independent MDA-MB-231, breast cancer cell lines. Anticancer Res 19 (1999) 269-275
9. Byrne C., Schairer C., Wolfe J., et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87 (1995) 1622-1629
10. Boyd N.F., Martin L.J., Rommens J.M., et al. Mammographic density: a heritable risk factor for breast cancer. Methods Mol Biol 472 (2009) 343-360
11. Stone J., Dite G.S., Gunasekara A., et al. The heritability of mammographically dense and nondense breast tissue. Cancer Epidemiol Biomarkers Prev 15 (2006) 612-617
12. Douglas J.A., Roy-Gagnon M.H., Zhou C., et al. Mammographic breast density-evidence for genetic correlations with established breast cancer risk factors. Cancer Epidemiol Biomarkers Prev 17 (2008) 3509-3516
13. O'Meara E.S., Rossing M.A., Daling J.R., Elmore J.G., Barlow W.E., and Weiss N.S. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 93 (2001) 754-762
14. Holmberg L., Iversen O.-E., Rudenstam C.M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100 (2008) 475-482
15. von Schoultz E., Rutqvist L.E., and Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial. J Natl Cancer Inst 97 (2005) 533-535